Synonym develops biomanufacturing infrastructure and process engineering expertise focused on microbial fermentation and gas fermentation for sustainable food and single-cell protein production. The company plans to use recent funding to conduct comparative techno-economic assessments of single-cell protein production across various gas fermentation techniques. Synonym will compare gas-based processes to plant-based carbon source processes such as those using dextrose, targeting potential financial and scalability benefits. Its team of process engineering and capital markets experts will evaluate capital expenditures and comprehensive operating expenses, including nutrient media, staffing, utilities, and related costs. Synonym recently published The State of Global Fermentation Report, which highlights existing microbial fermentation capacity, profitability drivers, and the need for facilities that support ongoing technological advancement to avoid obsolescence. The company emphasizes scale as a key factor in achieving price parity and advancing commercial viability. Synonym Biotechnologies is developing, financing and building productized, commercial-scale bio-manufacturing facilities—called “fermentation farms”—to serve non-pharmaceutical synthetic biology producers. Founded in January 2022, the company is creating standardized facility designs and underwriting standards so producers can make bioproducts at lower cost and higher quality than existing options. Synonym is also building an underwriting model to provide ESG investors access to a carbon-negative bio-manufacturing asset class. The startup raised $6.3 million in pre-seed capital to build its launch team and establish its product in the market. Management says it will use the funds to hire across design, engineering and finance, catalyze facility development, and accelerate outreach for strategic partnerships. The company expects to break ground on its first facility in Q3 2023 and will announce construction, architecture and development partners in coming months. Synonym cites a recent U.S. executive order on bio-manufacturing and emphasizes that reaching cost parity with legacy products is necessary for mass adoption.

Total raised

$6M

Funding rounds

2

Latest round

Seed

Latest activity

Oct 2022